Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PJPragya Jain

Discussion

Loading...

Member takes

Overview

Systematic review and meta analysis reveals MRD negativity predicts better clinical outcomes in AML patients treated with venetoclax and hypomethylating agents, highlighting its value as a prognostic

Key Points

  • To quantify the survival advantage of MRD negativity in AML patients undergoing venetoclax-based therapy.
  • Conducted a systematic review and meta analysis of studies from PubMed, Embase, and Cochrane
  • Included 6 studies with 562 adult patients with newly diagnosed or relapsed/refractory AML
  • Calculated pooled hazard ratios for overall survival, event-free survival, and relapse/progression-free survival
  • MRD negativity linked to improved survival outcomes across all measures
  • Pooled HR for overall survival was 0.31, indicating a significant survival benefit
  • Highest relative benefit was observed in relapse/progression-free survival with HR 0.15

Cite This Study

Pragya Jain (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b9https://doi.org/10.1182/blood-2025-1742
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025
  2. 2Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine2025 · 1 citations
  3. 3Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.2025
  4. 4Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT).2026
  5. 5Multilayer profiling of MRD in patients with relapsed/refractory CLL treated with venetoclax-based regimens in a real-world setting2025 · 1 citations